Here’s a quick rundown of our video takeaways—pulled from recent newsletters. Enjoy!
Biotech’s Split Story: Winners, Losers & What’s Next
Large-cap biotech remains strong, while SMID-caps struggle amid cautious sentiment. Biotech showed resilience during the Deepseek AI panic but remains sensitive to interest rate news.
Regeneron’s stock is down over 40% due to Eylea HD struggles, but a recovery is expected in 2H25. Gilead beat Q4 expectations, gaining 7.7%, though Q1 seasonality could test investor patience. AI-driven biotech names like Recursion and Schrödinger are outperforming, while broader SMID-cap sentiment remains weak.
Regulatory shifts, including the FDA’s withdrawal of diversity guidance and potential Medicare drug pricing revisions under Trump, could reshape the industry. M&A and IPO activity are picking up, signaling early signs of market recovery.
Upcoming Newsletter Events
February 2025: Video podcast featuring an expert discussing the process of Biotech R&D development.
February/March 2025: Video podcast exploring how biotech business development (BD) works.
Biotech Capital Compass: February Newsletter
Welcome to the Biotech Capital Compass, a newsletter dedicated to active investors, swing traders, and those passionate about the biotechnology (biotech) sector. Whether you're a day trader, a buy-and-hold investor, or simply fascinated by the potential of biotech, this newsletter will offer valuable insights, analysis, and opportunities tailored to your needs.
Starting January 2025, Biotech Capital Compass will transition to a paid subscription model, following three months of free content. We’re building a community of savvy biotech investors, so get in early to gain exclusive market insights and actionable strategies.
Disclosures at end of note.
About the Author
Hartaj Singh brings over 30 years of experience in drug development, corporate strategy, hedge fund management, and biotech analysis. With a career spanning top investment banks, Hartaj has been a highly ranked analyst, known for providing astute guidance on biotech investments for over a decade. His deep sector knowledge, honed through years of navigating the biotech landscape, is now being put to use to help investors capitalize on biotech opportunities.
Listen to this episode with a 7-day free trial
Subscribe to The Biotech Capital Compass to listen to this post and get 7 days of free access to the full post archives.
